ArticleJournal of virology2022
Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Open access · greenAbstract read
In one paragraph
Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 25 citations in OpenAlex.
- Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023Trial
- Minor differences in the untranslated regions of measles vector additional transcription units are reflected by differential immunogenicity of encoded MERS-CoV Spike antigen.Journal of virology · 2026Article
- Current Advances and Applications of Animal Models in SARS-CoV-2 Pathogenesis and Vaccine Development.Microorganisms · 2025Review
- Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- COVID-19 drug discovery and treatment options.Nature reviews. Microbiology · 2024Review
- COVID-19 therapeutics.Clinical microbiology reviews · 2024Review
- High diagnostic accuracy of quantitative SARS-CoV-2 spike-binding-IgG assay and correlation withHeliyon · 2024Article
- High interleukin-6 levels induced by COVID-19 pneumonia correlate with increased circulating follicular helper T cell frequency and strong neutralization antibody response in the acute phase of Omicron breakthrough infection.Frontiers in immunology · 2024Observational
- Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.Human vaccines & immunotherapeutics · 2023Article
- Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2023Article
- A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes.Virus research · 2023Article
- Identification of SARS-CoV-2 MNature communications · 2023Article
- Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Children's Hospital: A Contribution to a Still Inadequate Body of Evidence.Children (Basel, Switzerland) · 2023Article
- Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants.Scientific reports · 2023Article
- SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.Microbiology spectrum · 2022Article
- COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes.Clinical microbiology reviews · 2022Review
- Article
- A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response.bioRxiv : the preprint server for biology · 2022Article
- A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT).Life (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Yuki TakamatsuDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.ORCID 0000-0001-7967-1576
Masaki ImaiDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyogrid.26999.3d, Tokyo, Japan.
Kenji MaedaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Noriko NakajimaDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
Nobuyo Higashi-KuwataDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Kiyoko Iwatsuki-HorimotoDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyogrid.26999.3d, Tokyo, Japan.ORCID 0000-0002-8266-020X
Mutsumi ItoDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyogrid.26999.3d, Tokyo, Japan.
Maki KisoDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyogrid.26999.3d, Tokyo, Japan.
Tadashi MaemuraDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyogrid.26999.3d, Tokyo, Japan.
Yuichiro TakedaDepartment of Respiratory Medicine, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Kazumi OmataCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Tadaki SuzukiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
Yoshihiro KawaokaDivision of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyogrid.26999.3d, Tokyo, Japan.ORCID 0000-0001-5061-8296
Hiroaki MitsuyaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.ORCID 0000-0001-9274-3853
National Center for Global Health and Medicine · JPNational Institute of Infectious Diseases · JPNational Institutes of Health · USUniversity of Wisconsin–Madison · US
Funding
Development of therapeutics for SARS-CoV-2 infectionZIABC012018 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MITSUYA, HIROAKI · 2020 to 2025
$2.6MHHS | National Institutes of Health (NIH)Japan Agency for Medical Research and Development (AMED) JP19fk0108113Japan Agency for Medical Research and Development (AMED) JP20fk0108160Japan Agency for Medical Research and Development (AMED) JP20fk0108502Ministry of Health, Labour and Welfare (MHLW) JPMH20HA1006National Center for Global Health and Medicine (NCGM) 20A2003DNIAID NIH HHS HHSN272201400008C
Abstract
Despite various attempts to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients with COVID-19 convalescent plasmas, neither appropriate approach nor clinical utility has been established. We examined the efficacy of administration of highly neutralizing COVID-19 convalescent plasma (
Indexed as
LungVirus ReplicationAnimalsChlorocebus aethiopsCOVID-19COVID-19 SerotherapyDisease Models, AnimalHumansImmunization, PassiveMaleMesocricetusSARS-CoV-2Vero Cellsconvalescent plasma therapyCOVID-19SARS-CoV-2Syrian hamster COVID-19 model
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.